Literature DB >> 22657257

[Benefit of bladder and upper urinary tract urothelial tumors lymph node dissection: review from the Bladder Cancer Committee of the French National Association of Urology ("CC-AFU Vessie")].

S Larré1, H Quintens, N Houéde, E Compérat, C Roy, G Pignot, M Rouprêt, Y Neuzillet, H Wallerand, M Soulié, C Pfister.   

Abstract

INTRODUCTION: Lymph node dissection during radical cystectomy or nephroureterectomy confers improved prognosis and eventually therapeutic advantage. The aim of this update is to clarify the anatomical limits of the lymph node dissection, imaging related techniques, possible difficulties related to pathological analysis, its prognostic value and adjuvant treatments.
METHOD: A literature review was performed using PubMed database with a combination of the following keywords: "urothelial carcinoma", "lymph node excision", "imaging", "pathology analysis", "prognosis", "chemotherapy" and "radiotherapy".
RESULTS: Regarding bladder tumours, extended lymph node dissection is usually performed up to the division of the iliac vessels and the crossing of the ureters. The CT scan is the recommended imaging technique for lymph node staging but its sensitivity is low. Pathological examination should include perivesicle lymph nodes analysis and report the number of normal and metastatic lymph nodes separately. The prognosis is correlated to the total number of lymph nodes removed and to the extent of the excision. The lymph node density (number of metastatic nodes/normal nodes) is the most important prognosis factor. Adjuvant chemotherapy has not demonstrated a clear advantage. Its most efficient modality is a combination including cisplatin. For upper urinary tract tumours, lymph node dissection may have an impact on survival but definitive conclusion is limited by the lack of surgical technique and indications standardisation.
CONCLUSION: Extended lymph node dissection improves survival of bladder cancer and prognosis assessment that could eventually be used to stratify patient requiring adjuvant treatment (level of evidence 3). Improvement on survival was also suggested for upper urinary tract tumors (level of evidence 4).
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22657257     DOI: 10.1016/j.purol.2012.02.002

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  1 in total

1.  Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.

Authors:  Mathieu Orré; Igor Latorzeff; Aude Fléchon; Guilhem Roubaud; Véronique Brouste; Richard Gaston; Thierry Piéchaud; Pierre Richaud; Olivier Chapet; Paul Sargos
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.